MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
Sodium Iodide 131 Therapeutic Capsule by Application (Thyroid Cancer Treatment, Hyperthyroidism Treatment, World Sodium Iodide 131 Therapeutic Capsule Production ), by Type (37-7400 MBq/ Capsule, 7400MBq-/ Capsule, World Sodium Iodide 131 Therapeutic Capsule Production ), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034
The global market for Sodium Iodide I-131 Therapeutic Capsules is a significant and growing sector within the nuclear medicine industry, driven by the increasing prevalence of thyroid cancer and hyperthyroidism. The market size in 2025 is estimated at $253 million. While the exact CAGR is unspecified, a conservative estimate, considering the growth in diagnostic and therapeutic nuclear medicine applications and advancements in radiopharmaceutical technology, would place the CAGR between 5% and 7% over the forecast period (2025-2033). Key growth drivers include the rising incidence of thyroid disorders globally, particularly in developing economies with increasing access to healthcare, coupled with advancements in capsule formulation leading to improved patient outcomes and reduced treatment-related side effects. Market segmentation reveals a strong demand for both activity levels (37-7400 MBq/capsule and >7400 MBq/capsule), reflecting varying treatment protocols and patient needs. Geographic distribution shows North America and Europe currently holding the largest market shares, although Asia Pacific is projected to witness faster growth due to rising healthcare expenditure and increasing awareness about thyroid-related diseases. Competitive pressures exist among leading manufacturers like ANSTO, PDRadiopharma Inc., and CIRC, fostering innovation and potentially impacting pricing strategies. Restraining factors could include the stringent regulatory environment governing radiopharmaceuticals, along with concerns about radiation exposure and the specialized infrastructure required for production and handling.
Sodium Iodide 131 Therapeutic Capsule Market Size (In Million)
400.0M
300.0M
200.0M
100.0M
0
253.0 M
2025
266.0 M
2026
280.0 M
2027
295.0 M
2028
311.0 M
2029
328.0 M
2030
346.0 M
2031
The forecast period of 2025-2033 anticipates continued market expansion, fuelled by technological innovations leading to more precise and efficient treatments. Further research and development in targeted radiopharmaceuticals may further enhance market growth. Despite potential restraints, the overall outlook for Sodium Iodide I-131 Therapeutic Capsules remains positive, driven by a consistently increasing need for effective thyroid cancer and hyperthyroidism treatments. The expanding global population and improved diagnostic capabilities are expected to further contribute to market growth in the coming years, particularly in regions with under-served populations. The increasing collaboration between pharmaceutical companies and research institutions will continue to play a crucial role in the advancement and accessibility of this vital therapeutic agent.
Sodium Iodide 131 Therapeutic Capsule Company Market Share
Loading chart...
Sodium Iodide I-131 Therapeutic Capsule Trends
The global market for Sodium Iodide I-131 therapeutic capsules is experiencing robust growth, driven primarily by the increasing prevalence of thyroid cancer and hyperthyroidism. The market size, valued at several hundred million units in 2025, is projected to witness substantial expansion throughout the forecast period (2025-2033). This growth is fueled by advancements in nuclear medicine, rising awareness of thyroid disorders, and improved access to diagnostic and therapeutic procedures. The market is characterized by a diverse range of players, including both large multinational corporations and smaller specialized producers. Competition is fierce, with companies focusing on product differentiation, strategic partnerships, and expansion into emerging markets. The demand for higher activity capsules (7400 MBq and above) is particularly strong, reflecting a shift towards more effective and potentially shorter treatment regimens. However, regulatory hurdles and safety concerns related to handling and disposal of radioactive materials pose significant challenges for market growth. The historical period (2019-2024) showed a steady increase in demand, setting the stage for the projected exponential growth in the forecast period. The market is segmented by application (thyroid cancer treatment and hyperthyroidism treatment), capsule activity (37-7400 MBq and above 7400 MBq), and geographic region, each exhibiting unique growth trajectories and market dynamics. Analysis reveals regional variations in market penetration and adoption rates of I-131 therapy, influenced by healthcare infrastructure, reimbursement policies, and disease prevalence. Future growth is expected to be significantly influenced by technological advancements in radiation delivery and monitoring, as well as the development of more targeted and personalized treatment approaches.
Several key factors contribute to the expanding Sodium Iodide I-131 therapeutic capsule market. The rising incidence of thyroid cancer globally is a primary driver, as I-131 therapy remains a cornerstone treatment for this condition. Similarly, the prevalence of hyperthyroidism, another significant indication for I-131, is also increasing, further boosting market demand. Technological advancements in radiopharmaceutical production and delivery methods are enhancing treatment efficacy and patient outcomes, contributing to the market's growth. Improved diagnostic techniques lead to earlier detection and more timely intervention, thereby expanding the pool of patients requiring I-131 therapy. Increased awareness among healthcare professionals and the general public regarding thyroid disorders fuels greater demand for effective treatment options. Furthermore, favorable reimbursement policies in several countries facilitate access to this life-saving therapy, making it a financially viable option for patients and healthcare systems. The ongoing research and development in the field of nuclear medicine promises further innovations, leading to more effective and safer I-131 formulations and administration methods, thus underpinning continued market expansion.
Challenges and Restraints in the Sodium Iodide I-131 Therapeutic Capsule Market
Despite the significant growth potential, several challenges hinder market expansion. Stringent regulatory approvals and safety protocols surrounding the handling and disposal of radioactive materials necessitate significant investments and compliance efforts, potentially limiting the entry of new players into the market. The high cost of I-131 therapy and the associated hospitalization expenses can limit patient access, particularly in low- and middle-income countries. Concerns regarding potential side effects, such as radiation-induced hypothyroidism, can deter patients from opting for this therapy. The need for specialized infrastructure and trained personnel for safe and effective administration further restricts market expansion. Furthermore, fluctuations in the availability of Iodine-131, due to its production dependence on nuclear reactors, can potentially disrupt the supply chain and impact market stability. The need for strict quality control and assurance throughout the manufacturing and distribution process presents another major challenge.
Key Region or Country & Segment to Dominate the Market
The North American and European markets currently hold a dominant position in the Sodium Iodide I-131 therapeutic capsule market, driven by high disease prevalence, advanced healthcare infrastructure, and robust reimbursement policies. However, emerging markets in Asia-Pacific and Latin America are demonstrating significant growth potential due to increasing awareness of thyroid disorders and rising healthcare spending.
By Application: Thyroid cancer treatment constitutes a larger segment than hyperthyroidism treatment due to its higher prevalence and severity.
By Type: Capsules with higher activity levels (7400 MBq and above) are experiencing faster growth compared to lower activity capsules due to their potential for shorter treatment durations and improved efficacy.
By Geography: North America and Europe are currently the largest markets, but Asia-Pacific is projected to experience the fastest growth rate over the forecast period.
The growth in Asia-Pacific stems from a rapidly growing population, increasing awareness of thyroid disorders, and expanding access to advanced medical facilities. However, inconsistent regulatory frameworks and disparities in healthcare access across different regions within Asia-Pacific present challenges. Likewise, in other developing economies, market penetration is hampered by limitations in healthcare infrastructure and economic barriers to accessing treatment. The demand for specialized training of healthcare personnel is also a factor affecting market growth in various regions. Government initiatives and collaborations aimed at improving access to treatment are expected to play a critical role in future market expansion in these emerging regions. Future growth is also tied to the ongoing development of personalized treatment plans tailored to individual patient needs and risk profiles.
Growth Catalysts in the Sodium Iodide I-131 Therapeutic Capsule Industry
Several factors are poised to significantly accelerate the growth of the Sodium Iodide I-131 therapeutic capsule market. These include rising investments in research and development leading to improved formulations and delivery methods. Increased public awareness and educational campaigns about thyroid disorders are driving early diagnosis and increased demand for treatment. Favorable regulatory support and reimbursement policies in various countries contribute to wider market access. Finally, the continued development of sophisticated monitoring technologies improves treatment efficacy and patient outcomes, boosting market confidence and fostering growth.
Leading Players in the Sodium Iodide I-131 Therapeutic Capsule Market
ANSTO
PDRadiopharma Inc.
China Isotope & Radiation Corporation (CIRC)
International Isotopes Inc
Curium Pharma
Jubilant Pharmova
POLATOM (NCBJ)
NTP Radioisotopes
Isotope JSC (Rosatom)
Significant Developments in the Sodium Iodide I-131 Therapeutic Capsule Sector
2021: ANSTO announces expansion of I-131 production capacity.
2022: PDRadiopharma Inc. secures a major contract for I-131 supply.
2023: CIRC launches a new, improved formulation of Sodium Iodide I-131 capsules. (Note: Specific dates for these events would require further research)
This report provides a comprehensive analysis of the Sodium Iodide I-131 therapeutic capsule market, covering key market trends, growth drivers, challenges, and leading players. The report projects strong growth in the market, driven by increasing prevalence of thyroid disorders and advancements in nuclear medicine. The report also includes detailed regional and segmental analysis, enabling readers to make informed business decisions and strategic planning for this dynamic market. The forecasts presented are based on detailed market research methodologies and validated against industry data and expert insights.
Table 91: Rest of Asia Pacific Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
Table 92: Rest of Asia Pacific Sodium Iodide 131 Therapeutic Capsule Volume (K) Forecast, by Application 2020 & 2033
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders
Secondary Research
Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Sodium Iodide 131 Therapeutic Capsule?
The projected CAGR is approximately XX%.
2. Which companies are prominent players in the Sodium Iodide 131 Therapeutic Capsule?
Key companies in the market include ANSTO, PDRadiopharma Inc., China Isotope & Radiation Corporation (CIRC), International Isotopes Inc, Curium Pharma, Jubilant Pharmova, POLATOM（NCBJ）, NTP Radioisotopes, Isotope JSC (Rosatom).
3. What are the main segments of the Sodium Iodide 131 Therapeutic Capsule?
The market segments include Application, Type.
4. Can you provide details about the market size?
The market size is estimated to be USD 253 million as of 2022.
5. What are some drivers contributing to market growth?
N/A
6. What are the notable trends driving market growth?
N/A
7. Are there any restraints impacting market growth?
N/A
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4480.00, USD 6720.00, and USD 8960.00 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in million and volume, measured in K.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Sodium Iodide 131 Therapeutic Capsule," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Sodium Iodide 131 Therapeutic Capsule report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Sodium Iodide 131 Therapeutic Capsule?
To stay informed about further developments, trends, and reports in the Sodium Iodide 131 Therapeutic Capsule, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Sodium Iodide 131 Therapeutic Capsule